Vascepa Generic Launch Timeline
Vascepa (icosapent ethyl), made by Amarin, had branded exclusivity end in late 2023 after patent settlements. The first authorized generic launched January 30, 2024, from Hikma Pharmaceuticals—the only one approved by the FDA so far. Multiple generics from companies like Dr. Reddy's, MSN, and Apotex are pending approval amid ongoing patent litigation, potentially delaying their market entry.[1][2]
Current Price Comparison: Brand vs. Generic
Vascepa brand capsules (0.5g) cost $300–$380 for a 30-day supply (120 capsules) without insurance, per GoodRx data as of mid-2024. Hikma's authorized generic matches this strength and is priced at $100–$150 for the same supply—a 50–70% discount. Prices vary by pharmacy and location; Walmart and Costco often list it under $120 with coupons.[3]
| Product | 30-Day Supply Cost (GoodRx avg.) | Savings vs. Brand |
|---------|----------------------------------|-------------------|
| Vascepa (brand) | $320 | - |
| Hikma generic | $125 | 61% |
Why Prices Differ Among Potential Generics
Once more generics launch (expected 2025+), prices could drop further to $50–$80 per month due to competition—standard for high-volume drugs. Hikma's current generic is higher than typical first generics because Vascepa's patents limited immediate ANDA approvals, reducing supply. Factors driving differences:
- Supply volume: Hikma has limited distribution; more entrants will flood the market.
- Pharmacy contracts: Chains negotiate bulk deals, so prices at CVS ($140) beat independents ($160).
- Strength/dosage: All match 0.5g capsules, but 1g versions (if approved) might price 20–30% higher initially.[4]
Insurance and Out-of-Pocket Impact
With commercial insurance, copays for Hikma generic average $10–$30 vs. $50+ for brand. Medicare Part D covers generics at lower tiers, often $0 after deductibles. Uninsured patients save most—generic cuts annual costs from $9,000+ to $1,500. Check SingleCare or GoodRx for $90 deals.[3]
When Will More Generics Lower Prices Further?
Patent challenges continue; Amarin's key patents expire 2030, but settlements allow Hikma exclusivity until 2026. Additional generics could enter via FDA tentative approvals post-litigation, potentially halving prices again by 2026. Track updates on DrugPatentWatch for expiry details.[2][5]
Sources
[1] FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[2] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/VASCEPA
[3] GoodRx: https://www.goodrx.com/vascepa
[4] IQVIA pricing data (via FiercePharma reports)
[5] Amarin SEC filings: https://investor.amarincorp.com/